Treatment of resistant chronic central serous chorioretinopathy via platelet-rich plasma with electromagnetic stimulation

Arslan U., ÖZMERT E.

REGENERATIVE MEDICINE, cilt.15, sa.8, ss.2001-2014, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 8
  • Basım Tarihi: 2020
  • Doi Numarası: 10.2217/rme-2020-0056
  • Dergi Adı: REGENERATIVE MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2001-2014
  • Anahtar Kelimeler: central serous chorioretinopathy, electromagnetic stimulation, growth factors, iontophoresis, magnovision, platelet-rich plasma
  • Ankara Üniversitesi Adresli: Evet

Özet

Background: To evaluate whether subtenon injection of platelet-rich plasma (PRP) with retinal electromagnetic stimulation (rEMS) is effective in therapy-resistant chronic central serous chorioretinopathy (CSCR). Design: Prospective, sequential. Materials & methods: The study included 22 eyes with resistant chronic CSCR. Cases receiving micropulse laser or additional photodynamic therapy, subtenon PRP, and subtenon PRP + rEMS were classified as times 1, 2 and 3, respectively. Results: At time 3, the mean best-corrected visual acuity was 85.7 and 97.0 letters before and after the procedures, respectively (p = 0.01). Submacular thickness improved by 17, 27 and 51% at times 1, 2 and 3 respectively. Conclusion: For treating resistant CSCR, subtenon PRP + rEMS should be considered as an effective and safe option.